Stroke Prevention in Atrial Fibrillation and Other Major Cardiac Sources of Embolism

被引:18
|
作者
Freeman, William D. [1 ,2 ]
Aguilar, Maria I. [3 ]
机构
[1] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Dept Crit Care, Jacksonville, FL 32224 USA
[3] Mayo Clin, Dept Neurol, Phoenix, AZ 85054 USA
关键词
D O I
10.1016/j.ncl.2008.07.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The frequency of cardioembolic stroke is expected to rise as the general population ages. Much of the increase may be attributed to atrial fibrillation, the most common cause of cardioembolic stroke and one that plays a substantial role in aging adults. Other sources of cardioembolic stroke may include ventricular thrombus from myocardial infarction, heart failure, structural heart defects such as patent foramen ovale (PFO), atrial septal aneurysm, proximal aortic atheroma, valvular heart disease, and endocarditis. Diagnostic studies, such as neuroimaging, ECG, and echocardiography, are helpful in uncovering cardioembolic sources of stroke. Medical therapy is predicated on the underlying mechanism. For example, warfarin may be indicated in certain patients who have atrial fibrillation, atrial, or ventricular thrombi, and PFO with atrial septal aneurysm and cryptogenic stroke in select young patients to prevent stroke. Newer diagnostic technologies, including multidetector CT and cardiac MRI, may be useful to diagnose cardiac causes of stroke when transesophageal echocardiography is indeterminate or cryptogenic stroke is present.
引用
收藏
页码:1129 / 1160
页数:32
相关论文
共 50 条
  • [41] The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation
    Minguet, Joan
    Sims, Helen M.
    Smith, Katherine H.
    Bramlage, Peter
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 5 - 15
  • [42] Rivaroxaban: A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    Natalie J. Carter
    Greg L. Plosker
    Drugs, 2013, 73 : 715 - 739
  • [43] Stroke prevention in atrial fibrillation - an update
    Haeusler, K. G.
    Breithardt, G.
    Endres, M.
    NERVENHEILKUNDE, 2012, 31 (06) : 409 - +
  • [44] Anticoagulation for Stroke Prevention in Atrial Fibrillation
    Krepostman, Nicolas
    Kramer, Holly J.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 80 (05) : 561 - 563
  • [45] Stroke prevention in patients with atrial fibrillation
    Ono, A
    Fujita, T
    JOURNAL OF CLINICAL NEUROSCIENCE, 2003, 10 (01) : 71 - 73
  • [46] Atrial fibrillation and stroke prevention in the community
    OConnell, JE
    Gray, CS
    AGE AND AGEING, 1996, 25 (04) : 307 - 309
  • [47] Dabigatran for stroke prevention in atrial fibrillation
    Hohnloser, S. H.
    Diener, H. -C.
    HAMOSTASEOLOGIE, 2012, 32 (03): : 216 - 220
  • [48] Stroke prevention in atrial fibrillation patients
    Marinigh, Ricarda
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) : 2331 - 2350
  • [49] Prevention of Stroke in Patients with Atrial Fibrillation
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1313): : 41 - 41
  • [50] Aspirin for prevention of stroke in atrial fibrillation
    Lip, Gregory Y. H.
    STROKE, 2006, 37 (07) : 1640 - 1640